AstraZeneca’s Soliris approved in Japan for paediatric gMG patients
The drug is the first to be approved in Japan to treat children and adolescents with generalised myasthenia gravis
Read More
Tag: Soliris
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
The authorisation would include certain patients with refractory generalised myasthenia gravis
Read More
EU expands approval of Alexion’s Soliris
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read More
EU approval for Alexion’s PNH drug Ultomiris
The decision allows use of the drug in patients with haemolysis with clinical symptoms indicative of high disease activity
Read More
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More
Alexion gears up to file new blood disorder drug
Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.
Read More
US expands use of Alexion rare disease therapy Soliris
Alexion’s rare disease therapy Soliris can now be used in the US to treat generalised myasthenia gravis in patients who are anti-acetylcholine receptor antibody-positive, offering this group the first new treatment option in more than 60 years.
Read More
NHS England orders national service to handle Soliris
NHS England has announced plans to establish a national service to treat the ultra-rare kidney condition Atypical Haemolytic Uraemic Syndrome (aHUS), and the administration of Alexion’s high-cost Soliris.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
